Viatris (VTRS) Cash from Financing Activities (2019 - 2026)
Viatris (VTRS) recorded quarterly Cash from Financing Activities of -$203.8 million in Q1 2026, up 13.79% quarter-over-quarter from -$236.4 million in Q4 2025, and up 56.36% on a YoY basis from -$130.3 million in Q1 2025.
Viatris (VTRS) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Viatris' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$203.8 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 56.36% year-over-year to -$203.8 million; the TTM figure through Mar 2026 stood at -$1.0 billion (up 76.42% YoY), while the FY2025 annual figure was -$1.3 billion, up 70.12% from the prior year.
- Cash from Financing Activities was -$203.8 million for Q1 2026 at Viatris, up from -$236.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of -$97.6 million in Q3 2023 to a low of -$1.6 billion in Q3 2024.
- Historically, Cash from Financing Activities has averaged -$706.3 million across 5 years, with a median of -$758.7 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 87.14% in 2023, then plunged 1576.95% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at -$1.3 billion in 2022, then surged by 30.4% to -$926.1 million in 2023, then plunged by 53.35% to -$1.4 billion in 2024, then surged by 83.35% to -$236.4 million in 2025, then increased by 13.79% to -$203.8 million in 2026.
- The last three Cash from Financing Activities figures came in at -$203.8 million (Q1 2026), -$236.4 million (Q4 2025), and -$228.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Viatris | - | - | 1.16 Bn | -203.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -203.80 Mn |
| Mar 31, 2026 | -203.80 Mn |
| Dec 31, 2025 | -236.40 Mn |
| Dec 31, 2025 | -236.40 Mn |
| Sep 30, 2025 | -228.10 Mn |
| Sep 30, 2025 | -228.10 Mn |
| Jun 30, 2025 | -362.40 Mn |
| Jun 30, 2025 | -362.40 Mn |
| Mar 31, 2025 | -467.00 Mn |
| Mar 31, 2025 | -467.00 Mn |
| Dec 31, 2024 | -1.42 Bn |
| Dec 31, 2024 | -1.42 Bn |
| Sep 30, 2024 | -1.64 Bn |
| Sep 30, 2024 | -1.64 Bn |
| Jun 30, 2024 | -847.90 Mn |
| Jun 30, 2024 | -847.90 Mn |
| Mar 31, 2024 | -425.60 Mn |
| Mar 31, 2024 | -425.60 Mn |
| Dec 31, 2023 | -926.10 Mn |
| Dec 31, 2023 | -926.10 Mn |